Which is good numbers in the cancer treatment arena.

>> “We look forward to continued constructive conversations with the FDA as we move forward in our plan to initiate a phase 3 trial in previously treated HNSCC mid-2024 and prepare for a potential phase 3 trial evaluating the combination of petosemtamab and pembrolizumab [Keytruda] in previously untreated patients."

I understand the caution, but I firmly believe oncologists need to get more aggressive with multi-line treatments.